DBVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, DBV Technologies SA (DBVT) does not appear to be a strong buy for a beginner, long-term investor at this moment. The technical indicators are bearish, there are no recent positive trading signals, and the stock's recent price performance has been weak. While there is potential for future growth tied to the commercialization of Viaskin Peanut, the lack of immediate positive catalysts and mixed analyst ratings suggest a 'hold' recommendation for now.
The technical indicators for DBVT are bearish. The MACD is negatively expanding, RSI is neutral at 29.573, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 15.626), with resistance levels significantly higher (R1: 17.994). This indicates a lack of upward momentum in the short term.
Citizens analysts raised the price target twice in recent months, citing strong potential for Viaskin Peanut's commercialization and significant market share in young children. The firm projects peak U.S. sales around $3B, making the current valuation attractive relative to biotech acquisitions.
Goldman Sachs recently lowered its price target and maintains a Sell rating, which reflects skepticism about the company's near-term prospects. Additionally, there are no significant hedge fund or insider trading trends, and no recent news or congress trading data to act as positive catalysts.
No financial data available for analysis.
Mixed analyst ratings. Citizens maintains an Outperform rating with a price target increase to $55, citing strong commercialization potential for Viaskin Peanut. However, Goldman Sachs lowered its price target to EUR 1.01 and maintains a Sell rating, reflecting divergent views on the stock's future performance.
